# **Type 2 Diabetes Pharmacotherapy Reference**

*Clinical Decision Support \- Drug Classes and Trial Evidence*

*Primary Source: ADA Standards of Care in Diabetes—2026, Section 9: Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 2026;49(Suppl. 1):S183–S215. DOI: https://doi.org/10.2337/dc26-S009*

# **SGLT-2 Inhibitors**

| Mechanism | Inhibits sodium-glucose cotransporter 2 in proximal tubule; promotes urinary glucose excretion |
| :---- | :---- |
| A1C Efficacy | Intermediate to High |
| Weight Effect | Loss (intermediate) |
| Hypoglycemia Risk | Low |
| Renal Dosing | Can initiate if eGFR ≥20; continue for cardiorenal benefit until dialysis/transplant |

## **Key Benefits**

• MACE reduction (canagliflozin, empagliflozin)

• HF hospitalization reduction

• CKD progression slowing

## **Cautions**

• DKA risk in insulin-deficient states

• Genital mycotic infections

• Volume depletion

• Glucose-lowering reduced at eGFR \<45

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Empagliflozin (Jardiance) | Yes | Yes | Yes |
| Canagliflozin (Invokana) | Yes | Yes | Yes |
| Dapagliflozin (Farxiga) | Yes | Yes | Yes |
| Ertugliflozin (Steglatro) | No | Yes | No |
| Bexagliflozin (Brenzavy) | No | No | No |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| EMPA-REG OUTCOME | 14% MACE reduction; 38% CV death reduction in T2D with established CVD | N Engl J Med 2015;373:2117-28 |
| EMPEROR-Reduced | 25% reduction in CV death/HF hospitalization in HFrEF | N Engl J Med 2020;383:1413-24 |
| EMPA-KIDNEY | 28% reduction in CKD progression or CV death | N Engl J Med 2023;388:117-27 |
| CANVAS Program | 14% MACE reduction in T2D with high CV risk | N Engl J Med 2017;377:644-57 |
| CREDENCE | 30% reduction in renal composite endpoint in T2D with CKD | N Engl J Med 2019;380:2295-306 |
| DAPA-HF | 26% reduction in CV death/worsening HF in HFrEF | N Engl J Med 2019;381:1995-2008 |
| DAPA-CKD | 39% reduction in renal composite; benefit regardless of diabetes status | N Engl J Med 2020;383:1436-46 |

# **GLP-1 Receptor Agonists (GLP-1 / GIP)**

| Mechanism | Incretin mimetic; enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, promotes satiety |
| :---- | :---- |
| A1C Efficacy | High to Very High |
| Weight Effect | Loss (intermediate to very high) |
| Hypoglycemia Risk | Low |
| Renal Dosing | No dose adjustment for dulaglutide, liraglutide, semaglutide; avoid lixisenatide/exenatide if eGFR ≤30 |

## **Key Benefits**

• MACE reduction (dulaglutide, liraglutide, semaglutide)

• Albuminuria reduction

• MASH/MASLD improvement (semaglutide)

• Significant weight loss

## **Cautions**

• GI side effects (nausea, vomiting, diarrhea)

• Pancreatitis (rare)

• Thyroid C-cell tumors in rodents

• Hold before procedures requiring anesthesia

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Semaglutide injectable (Ozempic) | Yes | Yes | Yes |
| Semaglutide oral (Rybelsus) | Yes | No | No |
| Liraglutide (Victoza) | Yes | No | No |
| Dulaglutide (Trulicity) | Yes | No | No |
| Exenatide ER (Bydureon) | No | No | No |
| Exenatide (Byetta) | No | No | No |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| SUSTAIN-6 | 26% MACE reduction in T2D with high CV risk | N Engl J Med 2016;375:1834-44 |
| FLOW | 24% reduction in kidney disease progression and CV death in T2D with CKD | N Engl J Med 2024;391:109-21 |
| SELECT | 20% MACE reduction in overweight/obesity with CVD (without diabetes) | N Engl J Med 2023;389:2221-32 |
| STEP-HFpEF | Improved HF symptoms and functional status in HFpEF with obesity | N Engl J Med 2023;389:1069-84 |
| ESSENCE | MASH resolution without worsening fibrosis; FDA approved for MASH | N Engl J Med 2025;392:2089-99 |
| LEADER | 13% MACE reduction; 22% CV death reduction in T2D with high CV risk | N Engl J Med 2016;375:311-22 |
| REWIND | 12% MACE reduction in T2D with and without established CVD | Lancet 2019;394:121-30 |

# **Dual GIP/GLP-1 Receptor Agonists (GLP-1 / GIP)**

| Mechanism | Dual incretin agonist; activates both GIP and GLP-1 receptors for enhanced glucose-dependent insulin secretion and satiety |
| :---- | :---- |
| A1C Efficacy | Very High |
| Weight Effect | Loss (very high) |
| Hypoglycemia Risk | Low |
| Renal Dosing | No dose adjustment required |

## **Key Benefits**

• Superior A1C reduction vs GLP-1 RAs

• Superior weight loss vs GLP-1 RAs

• HF benefit in HFpEF with obesity

• Potential MASH benefit

## **Cautions**

• GI side effects similar to GLP-1 RAs

• May affect oral contraceptive absorption during titration

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Tirzepatide (Mounjaro) | Pending | Yes | Pending |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| SURPASS-2 | Superior A1C reduction vs semaglutide 1mg (up to 2.3% reduction) | N Engl J Med 2021;385:503-15 |
| SURPASS-4 | Superior A1C reduction vs insulin glargine in T2D with high CV risk | Lancet 2021;398:1811-24 |
| SUMMIT | 38% reduction in CV death/worsening HF in HFpEF with obesity | N Engl J Med 2025;392:427-37 |
| SYNERGY-NASH | Phase 2: MASH resolution in 44-62% vs 10% placebo | N Engl J Med 2024;391:299-310 |

# **DPP-IV Inhibitor**

| Mechanism | Inhibits dipeptidyl peptidase-4; increases endogenous incretin levels |
| :---- | :---- |
| A1C Efficacy | Intermediate |
| Weight Effect | Neutral |
| Hypoglycemia Risk | Low |
| Renal Dosing | Dose adjustment required for sitagliptin, saxagliptin, alogliptin; no adjustment for linagliptin |

## **Key Benefits**

• Well tolerated

• Weight neutral

• Oral administration

## **Cautions**

• No CV or renal benefit demonstrated

• Potential HF risk with saxagliptin

• Do not combine with GLP-1 RAs

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Sitagliptin (Januvia) | No | Risk suspected | No |
| Linagliptin (Tradjenta) | No | Risk Suspected | No |
| Saxagliptin (Onglyza) | No | Risk | No |
| Alogliptin (Nesina) | No | Risk Suspected | No |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| TECOS | CV safety confirmed; no MACE or HF benefit | N Engl J Med 2015;373:232-42 |
| CARMELINA | CV and renal safety confirmed; no benefit | JAMA 2019;321:69-79 |
| SAVOR-TIMI 53 | CV safety confirmed but 27% increased HF hospitalization risk | N Engl J Med 2013;369:1317-26 |

# **Biguanides**

| Mechanism | Reduces hepatic glucose production; improves insulin sensitivity |
| :---- | :---- |
| A1C Efficacy | High |
| Weight Effect | Neutral to modest loss |
| Hypoglycemia Risk | Low |
| Renal Dosing | Contraindicated if eGFR \<30; reduce dose if eGFR 30-45; caution initiation if eGFR \<45 |

## **Key Benefits**

• First-line therapy for decades

• Low cost; widely available

• Potential CV mortality benefit (UKPDS)

## **Cautions**

• GI side effects (use extended-release to mitigate)

• Vitamin B12 deficiency with long-term use

• Lactic acidosis risk (very rare)

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Metformin IR (Glucophage) | Yes | N/A | KDIGO recommends as first line prevention |
| Metformin ER (Glucophage XR) | Yes | N/A | KDIGO recommends as first line prevention |

# **Sulfonylurea (SUR-1)**

| Mechanism | Stimulates insulin secretion from pancreatic beta cells independent of glucose |
| :---- | :---- |
| A1C Efficacy | High |
| Weight Effect | Gain |
| Hypoglycemia Risk | High |
| Renal Dosing | Glyburide not recommended in CKD; use glipizide/glimepiride cautiously |

## **Key Benefits**

• Low cost

• Established efficacy

## **Cautions**

• Hypoglycemia risk (especially in elderly, CKD)

• Weight gain

• Possible reduced durability vs newer agents

\-Generally recommended to stop once basal insulin started, must stop once bolus insulin started

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Glimepiride (Amaryl) | Neutral | N/A | N/A |
| Glipizide (Glucotrol) | N/A | N/A | N/A |
| Glyburide (Diabeta) | N/A | N/A | N/A |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| CAROLINA | CV safety non-inferior to linagliptin | JAMA 2019;322:1155-66 |

# **Thiazolidinediones (TZDs)**

| Mechanism | PPAR-gamma agonist; improves insulin sensitivity in peripheral tissues |
| :---- | :---- |
| A1C Efficacy | High |
| Weight Effect | Gain |
| Hypoglycemia Risk | Moderate |
| Renal Dosing | No dose adjustment; generally not recommended due to fluid retention risk |

## **Key Benefits**

• Durable glycemic effect

• Potential MASH benefit

• Low cost

## **Cautions**

• Heart failure risk (contraindicated in HF)

• Fluid retention

• Bone fracture risk

• Bladder cancer concern

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Pioglitazone (Actos) | Potential | Risk | N/A |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| PROactive | 16% reduction in secondary composite (death, MI, stroke); HF hospitalization increased | Lancet 2005;366:1279-89 |

# **Basal Insulins**

| Mechanism | Exogenous insulin replacement; suppresses hepatic glucose production |
| :---- | :---- |
| A1C Efficacy | High to Very High |
| Weight Effect | Gain |
| Hypoglycemia Risk | High |
| Renal Dosing | Lower doses required as eGFR declines |

## **Key Benefits**

• No ceiling on glucose-lowering efficacy

• Required for severe hyperglycemia or insulin deficiency

## **Cautions**

• Hypoglycemia

• Weight gain

• Injection burden

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Glargine U-100 (Lantus, Basaglar) | N/A | N/A | N/A |
| Glargine U-300 (Toujeo) | N/A | N/A | N/A |
| Degludec (Tresiba) | Neutral | N/A | N/A |
| NPH (Humulin N, Novolin N) | N/A | N/A | N/A |

## **Key Clinical Trials**

| Trial | Key Finding | Citation |
| :---- | :---- | :---- |
| DEVOTE | CV safety confirmed; 40% less severe hypoglycemia vs glargine | N Engl J Med 2017;377:723-32 |

# **Prandial (Bolus) Insulins**

| Mechanism | Rapid-acting insulin to cover postprandial glucose excursions |
| :---- | :---- |
| A1C Efficacy | High to Very High |
| Weight Effect | Gain |
| Hypoglycemia Risk | High |
| Renal Dosing | Lower doses required as eGFR declines |

## **Key Benefits**

• Covers postprandial glucose spikes

• Flexibility in dosing

## **Cautions**

• Hypoglycemia

• Weight gain

• Multiple daily injections

## **Agents**

| Agent (Brand) | CV Benefit | HF Benefit | CKD Benefit |
| :---- | :---- | :---- | :---- |
| Lispro (Humalog, Lyumjev) | N/A | N/A | N/A |
| Aspart (Novolog, Fiasp) | N/A | N/A | N/A |
| Glulisine (Apidra) | N/A | N/A | N/A |

# **Clinical Decision Framework (ADA 2026 Figure 9.4)**

| Clinical Scenario | First-Line Recommendation | Notes |
| :---- | :---- | :---- |
| Established ASCVD | GLP-1 RA with proven CV benefit OR SGLT2i with proven CV benefit | Irrespective of A1C; for comprehensive CV risk reduction |
| High CV Risk | GLP-1 RA with proven CV benefit OR SGLT2i with proven CV benefit | Age ≥55 with ≥2 risk factors |
| Heart Failure (HFrEF/HFpEF) | SGLT2i with proven HF benefit | Add tirzepatide or semaglutide for HFpEF with obesity |
| CKD (eGFR 20-60 or albuminuria) | SGLT2i OR GLP-1 RA (semaglutide preferred) | On maximally tolerated ACEi/ARB |
| Weight Management Priority | Tirzepatide or Semaglutide (very high efficacy) | Dulaglutide, liraglutide also effective |
| MASLD/MASH | Semaglutide (FDA approved) OR Pioglitazone OR Tirzepatide | Consider combination therapy |

*Document prepared for clinical decision support. Always verify recommendations against current guidelines and individual patient factors.*